Skip to content
Adcetris(brentuximab vedotin)
Adcetris (brentuximab vedotin) is an antibody pharmaceutical. Brentuximab vedotin was first approved as Adcetris on 2011-08-19. It is used to treat hodgkin disease and large-cell lymphoma immunoblastic in the USA. It has been approved in Europe to treat hodgkin disease and non-hodgkin lymphoma. The pharmaceutical is active against tumor necrosis factor receptor superfamily member 8.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
hemic and lymphatic diseasesD006425
immune system diseasesD007154
Trade Name
FDA
EMA
Adcetris
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Brentuximab vedotin
Tradename
Proper name
Company
Number
Date
Products
Adcetrisbrentuximab vedotinSeagen Inc.N-125388 RX2011-08-19
1 products
Labels
FDA
EMA
Brand Name
Status
Last Update
adcetris Biologic Licensing Application2020-12-31
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
hodgkin disease—D006689C81
large-cell lymphoma immunoblastic—D016400—
Agency Specific
FDA
EMA
Expiration
Code
brentuximab vedotin, Adcetris, Seagen Inc.
2029-11-10Orphan excl.
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01F: Monoclonal antibodies and antibody drug conjugates
— L01FX: Other monoclonal antibodies and antibody drug conjugates in atc
— L01FX05: Brentuximab vedotin
HCPCS
Code
Description
J9042
Injection, brentuximab vedotin, 1 mg
Clinical
Clinical Trials
170 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hodgkin diseaseD006689C81275091477
Large-cell lymphoma anaplasticD017728C84.6131411225
T-cell lymphomaD0163992411—8
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Non-hodgkin lymphomaD008228C85.97111—218
Large b-cell lymphoma diffuseD016403C83.3351——8
Mycosis fungoidesD009182C84.0341——8
T-cell lymphoma cutaneousD016410C84.A421—17
Primary cutaneous anaplastic large cell lymphomaD054446C86.6—21——3
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
T-cell lymphoma peripheralD016411C84.958——214
LymphomaD008223C85.936——18
Sezary syndromeD012751C84.122———4
B-cell lymphomaD01639314———4
Enteropathy-associated t-cell lymphomaD058527C86.2—4———4
Adult t-cell leukemia-lymphomaD015459C91.514———4
NeoplasmsD009369C8031———4
Germ cell and embryonal neoplasmsD009373—3———3
Lymphomatoid papulosisD017731C86.6—3———3
Diffuse sclerodermaD045743EFO_000040413———3
Show 32 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
T-cell leukemiaD0154581————1
RecurrenceD0120081————1
Myelodysplastic syndromesD009190D461————1
Ovarian neoplasmsD010051EFO_0003893C561————1
Triple negative breast neoplasmsD0647261————1
Stomach neoplasmsD013274EFO_0003897C161————1
Urinary bladder neoplasmsD001749C671————1
Uterine cervical neoplasmsD0025831————1
HivD006678O98.71————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameBRENTUXIMAB VEDOTIN
INNbrentuximab vedotin
Description
Brentuximab Vedotin (chimeric mab)
Classification
Antibody
Drug classsynthetic analogs of the dolastatin series; monoclonal antibodies
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID914088-09-8
RxCUI1147320
ChEMBL IDCHEMBL1742994
ChEBI ID—
PubChem CID—
DrugBankDB08870
UNII ID7XL5ISS668 (ChemIDplus, GSRS)
Target
Agency Approved
TNFRSF8
TNFRSF8
Organism
Homo sapiens
Gene name
TNFRSF8
Gene synonyms
CD30, D1S166E
NCBI Gene ID
943
Protein name
tumor necrosis factor receptor superfamily member 8
Protein synonyms
CD30, CD30L receptor, cytokine receptor CD30, Ki-1 antigen, Lymphocyte activation antigen CD30
Uniprot ID
Q6P4D9
Mouse ortholog
Tnfrsf8 (21941)
tumor necrosis factor receptor superfamily member 8 (Q60846)
Alternate
No data
Variants
Clinical Variant
No data
Financial
Adcetris - Seagen Inc.
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Adcetris - Takeda
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 4,452 documents
View more details
Safety
Black-box Warning
Black-box warning for: Adcetris
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
48 adverse events reported
View more details